Skip to main content

AI-powered lung ultrasound for TB in Africa

CAD LUS4TB is an EDCTP3-funded research project bringing together partners across Africa and Europe to improve tuberculosis diagnosis through AI-driven computer-assisted lung ultrasound in Benin, Mali and South Africa.

AI-powered lung ultrasound for TB in Africa

CAD LUS4TB is an EDCTP3-funded research project bringing together partners across Africa and Europe to improve tuberculosis diagnosis through AI-driven computer-assisted lung ultrasound in Benin, Mali and South Africa.

About tuberculosis

Tuberculosis (TB) is a preventable and treatable bacterial infection that mainly affects the lungs. TB still causes around 1.3 million deaths each year and remains the second leading cause of death in sub-Saharan Africa. Many people with TB show no symptoms, making early detection difficult. In primary healthcare, the lack of appropriate diagnostic tools, such as chest X-rays and molecular tests, contributes to missed or delayed diagnoses. There is a great need for accessible, affordable and scalable tools to support TB diagnosis and management.

Our approach

The CAD LUS4TB project builds on a novel AI-driven algorithm developed to interpret portable ultrasound images via smartphone, enabling healthcare workers to rule out TB and guide patient management quickly. With 3,000 adult patients in Benin, Mali and South Africa, CAD LUS4TB will evaluate this technology at the primary-care level, generating population-tailored evidence for integration into health policy.


The consortium is funded by Global Health EDCTP3 and includes the University of Stellenbosch in South Africa (SU), the Swiss Federal Technology Institute of Lausanne (EPFL) Laboratory for Intelligent Global Health and Humanitarian Technologies (LiGHT), the National Teaching Center for Pneumology & Tuberculosis in Benin (UAC), the University of Sciences of Mali (USSTB), the Swiss Centre Hospitalier Universitaire Vaudois (CHUV), the Swiss Tropical and Public Health Institute (Swiss TPH), the Institute of Tropical Medicine in Antwerp, Belgium (ITM), the Foundation for Innovative New Diagnostics (FIND) in Switzerland, and Butterfly Network, Inc (NYSE: BFLY) in the USA.


Our activities

Validation study

Assess the performance of expert- and AI-assisted lung ultrasound for TB screening across different primary care settings

AI model development

Develop and refine image-analysis models tailored to lung ultrasound and mobile device use

Implementation

Evaluate the barriers and facilitators for the uptake of AI-assisted lung ultrasound into routine healthcare, including its economic impact

Capacity strengthening

Support research and clinical capabilities by implementing programmes with point-of-care ultrasound training and AI workshops

Our mission

It is a long established fact that a reader will be distracted by the readable content of a page when looking at its layout. The point of using Lorem Ipsum is that it has a more-or-less normal distribution of letters, as opposed to using 'Content here, content here', making it look like readable English.

 

Where we work

It is a long established fact that a reader will be distracted by the readable content of a page when looking at its.

  • 3 study sites in Benin
  • 3 study sites in Mali
  • 2 study sites in South Africa

About Tuberculosis

Tuberculosis (TB) is a preventable and treatable bacterial infection that mainly affects the lungs. Despite this, TB still causes around 1.3 million deaths each year and remains the second leading cause of death in sub-Saharan Africa. Many people with TB show no symptoms, making early detection difficult. In primary healthcare, the lack of appropriate diagnostic tools, such as chest X-rays and molecular tests, contributes to missed or delayed diagnoses. There is a great need for accessible, affordable and scalable tools to support TB diagnosis and management.

Lorem ipsum

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Amet ullamcorper sed vitae quis turpis.

Lorem ipsum

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Amet ullamcorper sed vitae quis turpis.

Lore ipsum

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Amet ullamcorper sed vitae quis turpis.

How we work

Lorem Ipsum available, but the majority have suffered alteration in some form, by injected humor, or randomized words which don't look even slightly believable.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed et ut amet, sed in amet. Faucibus sit cursus dis sollicitudin. Viverra est amet, cras curabitur volutpat porttitor lacus.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed et ut amet, sed in amet. Faucibus sit cursus dis sollicitudin. Viverra est amet, cras curabitur volutpat porttitor lacus.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed et ut amet, sed in amet. Faucibus sit cursus dis sollicitudin. Viverra est amet, cras curabitur volutpat porttitor lacus.

What drives us

"I’m motivated by the potential of technology to close the gap in TB diagnosis. By combining AI and ultrasound, we can bring advanced diagnostics to the people and places that need them most."

Mary-Jane White

Researcher

"What drives me is knowing that our research on tuberculosis can directly improve lives. Every insight we gain brings us one step closer to more effective treatments and, ultimately, to ending this disease that still affects millions worldwide."

John Smith

Researcher